Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor.

	Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor.
	Brandhuber, Barbara 1; Ku, Karin 1; Lallena, Maria J.2; Baquero, Carmen 2; Choy, Regina 1; Ebata, Kevin 1; Lin, Sophie Shu 3; Jiang, Lihua 3; Liu, Yanxin 3; Chen, Xiangling 4
刊名	CANCER RESEARCH
	2021-07-01
卷号	81 期号:13 页码:1
ISSN号	0008-5472
WOS研究方向	Oncology
语种	英语
出版者	AMER ASSOC CANCER RESEARCH
WOS记录号	WOS:000680263506180
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/297645]
专题	中国科学院上海药物研究所
作者单位	1.Lilly, Loxo Oncol, Boulder, CO USA 2.Eli Lilly & Co, Madrid, Spain 3.Fochon Pharmaceut Ltd, Chongqing, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Brandhuber, Barbara,Ku, Karin,Lallena, Maria J.,et al. Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor.[J]. CANCER RESEARCH,2021,81(13):1.
APA	Brandhuber, Barbara.,Ku, Karin.,Lallena, Maria J..,Baquero, Carmen.,Choy, Regina.,...&Lou, Liguang.(2021).Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor..CANCER RESEARCH,81(13),1.
MLA	Brandhuber, Barbara,et al."Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor.".CANCER RESEARCH 81.13(2021):1.